- Home
- BTAI vs NOTV Comparison
BTAI vs NOTV Comparison
Compare BTAI & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- NOTV
- Stock Information
- Founded
- BTAI 2017
- NOTV 1974
- Country
- BTAI United States
- NOTV United States
- Employees
- BTAI N/A
- NOTV N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- NOTV Health Care
- Exchange
- BTAI Nasdaq
- NOTV Nasdaq
- Market Cap
- BTAI 52.7M
- NOTV 57.7M
- IPO Year
- BTAI 2018
- NOTV 1997
- Fundamental
- Price
- BTAI $3.79
- NOTV $1.64
- Analyst Decision
- BTAI Strong Buy
- NOTV Strong Buy
- Analyst Count
- BTAI 4
- NOTV 1
- Target Price
- BTAI $40.00
- NOTV $5.00
- AVG Volume (30 Days)
- BTAI 14.1M
- NOTV 399.5K
- Earning Date
- BTAI 08-12-2025
- NOTV 08-06-2025
- Dividend Yield
- BTAI N/A
- NOTV N/A
- EPS Growth
- BTAI N/A
- NOTV N/A
- EPS
- BTAI N/A
- NOTV N/A
- Revenue
- BTAI $868,000.00
- NOTV $505,299,000.00
- Revenue This Year
- BTAI N/A
- NOTV $5.64
- Revenue Next Year
- BTAI $597.46
- NOTV $5.16
- P/E Ratio
- BTAI N/A
- NOTV N/A
- Revenue Growth
- BTAI N/A
- NOTV 0.85
- 52 Week Low
- BTAI $1.17
- NOTV $1.15
- 52 Week High
- BTAI $13.36
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- BTAI 48.02
- NOTV 41.47
- Support Level
- BTAI $3.41
- NOTV $1.56
- Resistance Level
- BTAI $4.20
- NOTV $1.85
- Average True Range (ATR)
- BTAI 0.62
- NOTV 0.11
- MACD
- BTAI -0.27
- NOTV -0.01
- Stochastic Oscillator
- BTAI 11.05
- NOTV 24.32
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.